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BACKGROUND: Individuals with type 1 diabetes mellitus (T1DM) have a 
high risk of cardiovascular complications, but it is unknown to what extent 
fulfilling all cardiovascular treatment goals is associated with residual risk 
of mortality and cardiovascular outcomes in those with T1DM compared 
with the general population.
METHODS: We included all patients ≥18 years of age with T1DM 
who were registered in the Swedish National Diabetes Register from 
January 1, 1998, through December 31, 2014, a total of 33 333 
patients, each matched for age and sex with 5 controls without diabetes 
mellitus randomly selected from the population. Patients with T1DM 
were categorized according to number of risk factors not at target: 
glycohemoglobin, blood pressure, albuminuria, smoking, and low-density 
lipoprotein cholesterol. Risk of all-cause mortality, acute myocardial 
infarction, heart failure hospitalization, and stroke was examined in relation 
to the number of risk factors at target.
RESULTS: The mean follow-up was 10.4 years in the diabetes group. 
Overall, 2074 of 33 333 patients with diabetes mellitus and 4141 of 
166 529 controls died. Risk for all outcomes increased stepwise for each 
additional risk factor not at target. Adjusted hazard ratios for patients 
achieving all risk factor targets compared with controls were 1.31 (95% 
confidence interval [CI], 0.93–1.85) for all-cause mortality, 1.82 (95% CI, 
1.15–2.88) for acute myocardial infarction, 1.97 (95% CI, 1.04–3.73) 
for heart failure hospitalization, and 1.17 (95% CI, 0.51–2.68) for stroke. 
The hazard ratio for patients versus controls with none of the risk factors 
meeting target was 7.33 (95% CI, 5.08–10.57) for all-cause mortality, 
12.34 (95% CI, 7.91–19.48) for acute myocardial infarction, 15.09 (95% 
CI, 9.87–23.09) for heart failure hospitalization, and 12.02 (95% CI, 
7.66–18.85) for stroke.
CONCLUSIONS: A steep-graded association exists between decreasing 
number of cardiovascular risk factors at target and major adverse 
cardiovascular outcomes among patients with T1DM. However, risks for 
all outcomes were numerically higher for patients with T1DM compared 
with controls, even when all risk factors were at target, with risk for 
acute myocardial infarction and heart failure hospitalization statistically 
significantly higher.
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People with type 1 diabetes mellitus (T1DM) are re-ported to have on average a 3- to 5-fold increased risk of cardiovascular disease (CVD) and death 
compared with the general population, with some evi-
dence that targeted tight glycemic control may favorably 
affect CVD risk.1 Even with a glycohemoglobin (HbA1c) 
below the target level of 6.9% (52 mmol/mol), the risk 
of CVD and mortality is still on average twice that of the 
general population.2,3
The benefits of targeting multiple risk factors are 
now well established in type 2 diabetes mellitus.4–6 Al-
though the evidence base for such efficacy in T1DM is 
not nearly as robust, intensive control of glycemia, blood 
pressure, and low-density lipoprotein cholesterol levels 
has also been shown to reduce the risk of cardiovas-
cular complications in patients with T1DM.1,7,8 Although 
preventive strategies for cardiovascular risk mitigation 
similar to those for patients with type 2 diabetes mellitus 
are recommended for patients with T1DM, it remains un-
known to what extent risk factor control may reduce the 
excess risk of death and CVD in T1DM.9
Our group has previously reported the excess risk of 
mortality and cardiovascular outcomes associated with 
increasing HbA1c in patients with T1DM.
2,10,11 In the pres-
ent study, we examined the excess risk of these out-
comes in patients with T1DM according to their overall 
CVD risk factor profile. The aim was to examine to what 
extent the excess CVD risks associated with T1DM could 
be potentially mitigated with optimal risk factor control.
We used the Swedish National Diabetes Register to 
study the associations between well-recognized modifi-
able risk factors (HbA1c, blood pressure, low-density li-
poprotein cholesterol, smoking, and albuminuria) with re-
spect to risk for mortality and cardiovascular outcomes 
associated with T1DM compared with matched popula-
tion controls.
METHODS
Commercial sponsorship was not received. The ethics com-
mittee of the University of Gothenburg, Gothenburg, Sweden, 
approved the study. All registered patients provided written 
informed consent before inclusion in the cohort.
Data Sources and Study Cohort
The Swedish National Diabetes Register was launched in 
199612 and includes information on risk factors, medications, 
and complications of diabetes mellitus. Virtually all Swedes 
≥18 years of age with T1DM are included. T1DM is defined for 
the National Diabetes Register on the basis of epidemiological 
data: treatment with insulin and a diagnosis at ≤30 years of 
age, which has been validated as accurate in 97% of cases, 
as previously reported.13,14 We included patients with at least 
1 registration between January 1, 1998, and December 31, 
2012. For the baseline, which was the first registration in the 
National Diabetes Register, each patient was matched for age, 
sex, and county with 5 controls (without diabetes mellitus) ran-
domly selected from the Swedish population.2
A total of 36 869 individuals with T1DM and 183 195 con-
trols were identified. From these, we excluded individuals with 
T1DM who met any of the following criteria: body mass index 
<18.5 kg/m2, history of acute myocardial infarction, stroke, 
heart failure, severe chronic kidney disease (stage ≥4), cor-
onary heart disease, and amputation. These patients were 
excluded, along with their matched controls. We excluded con-
trols individually (ie, without excluding their matched patients) 
if they fulfilled the same exclusion criteria (data on body mass 
index or other risk factors were not available for controls). 
A flowchart is presented in Figure I in the online-only Data 
Supplement.
Socioeconomic Covariables
We retrieved socioeconomic data from Statistics Sweden. 
Country of birth was dichotomized as born in Sweden or immi-
grant. Income was stratified into annual quintiles. Marital cat-
egories were single, married/registered partner, divorced, or 
widowed. Education was categorized into ≤9 years, 10 to 12 
years, and college or university degree.
Outcomes and Coexisting Conditions
Information on coexisting conditions, outcomes, and deaths 
was retrieved by linking data to the nationwide Swedish Inpatient 
Register and the Cause of Death Register. The Swedish 
Inpatient Registry includes all inpatient admissions since 
1987. Using the 9th and 10th revisions of the International 
Clinical Perspective
What Is New?
• It is unknown whether maintenance of cardiovascu-
lar risk factors at target could eliminate excess risk 
of mortality and cardiovascular disease associated 
with type 1 diabetes mellitus.
• We compared 33 333 patients with type 1 diabetes 
mellitus with 166 529 matched controls without 
type 1 diabetes mellitus.
• Patients with type 1 diabetes mellitus with 5 selected 
cardiovascular risk factors at target demonstrated a 
nonsignificant excess risk of death compared with 
controls.
• However, individuals with type 1 diabetes mellitus 
still had 82% and 97% elevated risk of myocardial 
infarction and heart failure, respectively, despite 
having all risk factors at target.
• For every incremental risk factor not at target, the 
excess risk of death and cardiovascular outcomes 
increased in a graded fashion.
What Are the Clinical Implications?
• Achievement of current evidence-based target lev-
els of 5 selected risk factors markedly reduces the 
excess risk of cardiovascular disease and may even 
eliminate the excess risk of mortality.
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Classification of Disease (ICD), we assessed the following ICD 
codes: coronary heart disease (410–414 [ICD-9], I20–I25 [ICD-
10], of which 410 and I21 coded acute myocardial infarction), 
stroke (431–434, 436 [ICD-9], I61–I64 [ICD-10]), and hospital-
ization for heart failure (428 [ICD-9], I50 [ICD-10]). The sensitiv-
ity and specificity for these diagnoses have been validated.15 
The outcomes used in this study were all-cause mortality, fatal/
nonfatal acute myocardial infarction (henceforth referred to as 
acute myocardial infarction), hospitalization for heart failure, 
and fatal/nonfatal stroke (henceforth referred to as stroke).
Variables Assessed in the National Diabetes 
Registry
We assessed body mass index, HbA1c, low-density lipoprotein 
cholesterol, total cholesterol, systolic and diastolic blood pres-
sures, use of lipid-lowering and antihypertensive medications, 
smoking, physical activity (categories: never, less than once 
a week, once or twice a week, 3–5 times per week, or daily), 
and estimated glomerular filtration rate (estimated with the 
Modification of Diet in Renal Disease equation). Albuminuria 
was defined as 2 positive tests of 3 samples taken within 1 
year, with microalbuminuria defined as urinary albumin-to-creat-
inine ratio of 3 to 30 mg/mmol or a urinary albumin clearance 
of 20 to 200 μg/min or 20 to 300 mg/L, and macroalbumin-
uria was defined as an urinary albumin-to-creatinine ratio >30 
mg/mmol or a urinary albumin clearance of >200 μg/min or 
>300 mg/L. Definitions for risk factors are listed in Table 1.
Definition of Risk Factor at Target and Main 
Objective
For the main analyses, in which we examined the risk of the 
outcomes in relation to the number of risk factors at target, we 
categorized patients with T1DM into 6 groups, defined by the 
number of risk factors not at target (ranging from 0–5 risk fac-
tors). Cutoffs chosen for continuous variables were based on a 
tradeoff between evidence base, guideline-recommended tar-
get levels, and optimizing statistical power within the observed 
data set. The following 5 risk factors were considered (cutoffs 
in parentheses): HbA1c (≥6.9% [≥53 mmol/mol]), systolic and 
diastolic blood pressures (either ≥140 mm Hg systolic or ≥80 
mm Hg diastolic), albuminuria (presence of microalbuminuria or 
macroalbuminuria), smoking (being a smoker at study entry), 
and low-density lipoprotein cholesterol (>3 mmol/L).
Statistical Methods
Excess Risk of Outcomes According to Risk Factor Control
We used the Multivariate Imputation by Chained Equations 
algorithm to impute missing data for patients with diabetes 
mellitus. Five complete data sets were imputed.15 Table I in 
the online-only Data Supplement lists the variables used in the 
imputation model. Table II and Figures II and III in the online-only 
Data Supplement show, along with the frequency of missing 
data elements, the distribution of each parameter before and 
after imputation.
Crude incidence rates were calculated for controls and for 
individuals with T1DM; for the latter group, incidence rates 
were calculated according to the number of risk factors at 
target. Crude incidence rate is expressed as the number of 
events per 10 000 person-years of observation. Exact Poisson 
confidence intervals (CIs) were used.
Using Cox regression, we examined the risk of each out-
come among individuals with T1DM compared with matched 
controls relation to number of risk factors not at target. We 
adjusted for income, education, marital status, immigrant sta-
tus, age, duration of diabetes mellitus, and status at baseline 
with regard to history of coexisting conditions. All models were 
stratified on sex to allow for different underlying baseline haz-
ards for men and women. To adjust for diabetes duration, we 
assigned controls to a duration of 0 years, and patients with 
diabetes mellitus had their duration centralized around the 
grand mean. Resulting hazard ratios represent the excess risk 
associated with T1DM at the mean duration of diabetes mel-
litus (18.3 years in the imputed data set). For total mortality, 
we included coronary heart disease, atrial fibrillation, and heart 
failure as comorbidities. For myocardial infarction, we included 
coronary heart disease, atrial fibrillation, and heart failure. For 
hospitalization for heart failure, we included atrial fibrillation 
and coronary heart disease, and for stroke, we included heart 
failure, atrial fibrillation, and coronary heart disease.
Calculations were performed in R (version 3.2.3) with the 
following packages: survival, rms, and mice (Stef van Buuren, 
Karin Groothuis-Oudshoorn, Alexander Robitzsch, Gerko Vink, 
Lisa Doove, Shahab Jolani [2015], and Multivariate Imputation 
by Chained Equations, R package version 2.25).
RESULTS
Study Population
After application of the restriction criteria, the final analy-
sis cohort comprised 33 333 individuals with T1DM and 
166 529 controls. A total of 9465 patients with diabe-
tes mellitus had complete data on all 5 risk factors, and 
23 868 individuals with diabetes mellitus had at least 1 
risk factor not at target. Table 2 presents baseline char-
acteristics and imputed data sets. Table II in the online-
only Data Supplement shows characteristics of the par-
ticipants with missing data on at least 1 risk factor. Mean 
Table 1. Definitions of Risk Factors for the Main 
Analyses*
Risk Factor Definition of Abnormal
Blood pressure Systolic blood pressure ≥140 
mm Hg or diastolic blood 
pressure ≥80 mm Hg
LDL-C Levels >3 mmol/L
Smoking Being a smoker at study entry
Albuminuria Presence of microalbuminuria or 
macroalbuminuria
HbA
1c ≥53 mmol/mol (≥6.9%)
HbA
1c
 indicates glycohemoglobin; and LDL-C indicates low-density 
lipoprotein cholesterol.
*Patients with type 1 diabetes mellitus are stratified by the number of 
risk factors present.
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age was 32 years, and 46% were women. Education, in-
come, and marital status did not differ between patients 
and controls. Coexisting conditions were more common 
among patients with diabetes mellitus. The number of 
patients with T1DM in each risk factor category was 
consistent among the original and all imputed data sets. 
Median follow-up was 10.4 years.
Risk for Mortality and Cardiovascular Outcomes
Figure 1A through 1D shows the number of events, event 
rates, and adjusted hazard ratios for all of the outcomes 
of interest. A total of 2074 patients with diabetes mel-
litus (6.2%) and 4141 controls (2.5%) died during the 
study period (Figure 1A). Mortality rates among patients 
with diabetes mellitus were lowest for those with all risk 
factors at target (1.58 [95% CI, 0.95–2.21] deaths per 
1000 person-years). The mortality rate for controls was 
2.55 (95% CI, 2.47–2.62) deaths per 1000 person-
years. The adjusted mortality hazard ratio for patients 
with T1DM with all risk factors at target compared with 
their controls was 1.31 (95% CI, 0.93–1.85). The corre-
sponding adjusted hazard ratio was 7.33 (95% CI, 5.08–
10.57) for those with none of the 5 risk factors at target.
Figure 1B presents corresponding estimates for acute 
myocardial infarction. Incidence rates among patients 
with diabetes mellitus were lowest for those with all risk 
factors at target (0.90 [95% CI, 0.44–1.36] events per 
1000 person-years). The adjusted hazard ratio for pa-
tients with T1DM versus controls with all risk factors at 
target was 1.82 (95% CI, 1.15–2.88). Having none of 
the 5 risk factors at target yielded an adjusted hazard 
ratio for patients with T1DM versus matched controls of 
12.34 (95% CI, 7.81–19.48).
Figure 1C shows corresponding estimates for heart 
failure. Rates for hospitalization for heart failure among 
patients with diabetes mellitus were lowest for those 
with all risk factors at target (0.61 [95% CI, 0.19–1.03] 
events per 1000 person-years). The adjusted hazard 
ratio with respect to heart failure for patients with all 
risk factors at target versus matched controls was 1.97 
(95% CI, 1.04–3.73). Having 5 risk factors yielded an 
adjusted hazard ratio for patients with diabetes melli-
tus compared with matched controls of 15.09 (95% CI, 
9.87–23.09) for heart failure.
Estimates for stroke are presented in Figure 1D. Ad-
justed hazard ratios for stroke increased to 12.02 (95% 
CI, 7.66–18.85) for patients with none of the risk factors 
at target. However, patients with all risk factors at target 
had a hazard ratio with point estimate much closer to 1 
(hazard ratio, 1.17; 95% CI, 0.51–2.68).
Men with T1DM with all risk factors at target demon-
strated an adjusted hazard ratio of 1.28 (95% CI, 0.80–
2.06) for all-cause mortality, whereas the corresponding 
hazard ratio for women was 1.32 (95% CI, 0.77–2.27; 
Figure 2).
Ancillary Analyses
We carried out a subgroup analysis of the 9465 individu-
als with T1DM who had complete data for all variables in 
Table 2. This was done to compare the estimates gener-
ated from the multiple imputation models with a com-
plete case analysis. We note that there were no material 
differences in cardiovascular outcomes and mortality, 
except for the larger CIs obtained in the complete case 
analysis; the risk pattern and point estimates, however, 
were highly comparable. Figure IV in the online-only Data 
Supplement provides details.
Long-Term Trends in Risk Factor Distribution
Figure V in the online-only Data Supplement shows that 
the proportion of patients having all risk factors at target 
doubled between 1998 and 2012 but still remained low 
at ≈11%. Figure VI in the online-only Data Supplement 
shows that causes of death differed between the groups 
studied. Dying of cancer was more common among 
controls, whereas cardiovascular and endocrine causes 
were more common among individuals with T1DM.
DISCUSSION
This prospective observational study of 33 333 patients 
with T1DM and 166 529 matched controls shows that 
patients with T1DM with 5 selected cardiovascular risk 
factors at target continued to display a clear excess risk 
for acute myocardial infarction and heart failure com-
pared with the general population. The excess risk for 
acute myocardial infarction and heart failure hospitaliza-
tion remained elevated by 82% and 97%, respectively, 
despite all risk factors being at target. We noted an ex-
cess risk of all-cause mortality and stroke with all risk 
factors at target, but the excess risk was not statisti-
cally significant. It is important to note that for each risk 
factor not at target, we identify a steep increase in the 
excess risks; eg, the excess risk of death increased in a 
striking fashion from a 31% increase to 633% higher risk 
in patients with T1DM with 5 risk factors at target versus 
no risk factors at target (both compared with matched 
controls). Thus, achievement of current target levels of 
these risk factors appears crucial to increase longevity 
in patients with T1DM.
Large observational studies have recently established 
an excess risk for death in patients with T1DM, even 
when HbA1c was at target, and a decreased life expec-
tancy in both men and women with T1DM compared with 
the general population.2,3 Unlike type 2 diabetes mellitus, 
the beneficial effect of multiple risk factor control on car-
diovascular outcomes in individuals with T1DM has not 
been studied in randomized trials.4,16 This prospective 
study includes one of the largest cohorts of patients with 
T1DM with a median follow-up of 10 years and detailed 
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All-cause mortality
Fatal/nonfatal acute myocardial infarction
GROUP
Matched controls
No risk factors
1 risk factor
2 risk factors
3 risk factors
4 risk factors
5 risk factors
EVENTS
1592
23
166
466
516
280
46
PERSON−YEARS
1620975
25834
95997
107865
62149
18668
2270
INCIDENCE RATE
 0.98 ( 0.93 to  1.03)
 0.90 ( 0.44 to  1.36)
 1.72 ( 1.41 to  2.04)
 4.32 ( 3.82 to  4.83)
 8.31 ( 7.23 to  9.39)
14.98 (12.92 to 17.04)
20.26 (11.85 to 28.67)
HAZARD RATIO
Reference
 1.82 (1.15 to  2.88)
 2.45 (2.01 to  2.98)
 3.98 (3.43 to  4.62)
 5.84 (4.94 to  6.91)
 9.64 (8.20 to 11.34)
12.34 (7.81 to 19.48)
1 2 3 4 5 6 7 8 9 11 13 15
Hazard ratio
Hospitalization for heart failure
GROUP
Matched controls
No risk factors
1 risk factor
2 risk factors
3 risk factors
4 risk factors
5 risk factors
EVENTS
1068
16
102
280
341
201
34
PERSON−YEARS
1623314
25873
96249
108722
62986
18962
2264
INCIDENCE RATE
 0.66 (0.62 to  0.70)
 0.61 (0.19 to  1.03)
 1.06 (0.73 to  1.39)
 2.57 (2.09 to  3.05)
 5.42 (4.58 to  6.25)
10.62 (8.78 to 12.47)
14.92 (8.45 to 21.38)
HAZARD RATIO
Reference
 1.97 (1.04 to  3.73)
 2.52 (1.85 to  3.41)
 3.82 (3.06 to  4.75)
 6.37 (5.06 to  8.03)
11.05 (8.94 to 13.66)
15.09 (9.87 to 23.09)
1 2 3 4 5 6 7 8 9 11 13 15 17
Hazard ratio
Fatal/nonfatal stroke
GROUP
Matched controls
No risk factors
1 risk factor
2 risk factors
3 risk factors
4 risk factors
5 risk factors
EVENTS
1448
13
102
236
295
172
30
PERSON−YEARS
1621184
25852
96111
108544
62854
19046
2266
INCIDENCE RATE
 0.89 (0.85 to  0.94)
 0.51 (0.06 to  0.96)
 1.06 (0.79 to  1.33)
 2.17 (1.81 to  2.54)
 4.70 (3.95 to  5.46)
 9.02 (7.42 to 10.62)
13.18 (7.03 to 19.32)
HAZARD RATIO
Reference
 1.17 (0.51 to  2.68)
 2.10 (1.64 to  2.68)
 2.84 (2.32 to  3.46)
 4.66 (3.84 to  5.65)
 8.09 (6.51 to 10.05)
12.02 (7.66 to 18.85)
1 2 3 4 5 6 7 8 9 10 12 14
Hazard ratio
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GROUP
Matched controls
No risk factors
1 risk factor
2 risk factors
3 risk factors
4 risk factors
5 risk factors
EVENTS
4141
41
286
642
676
360
69
PERSON−YEARS
1627074
25928
96572
109556
64068
19672
2411
INCIDENCE RATE
 2.55 ( 2.47 to  2.62)
 1.58 ( 0.95 to  2.21)
 2.97 ( 2.49 to  3.44)
 5.86 ( 5.16 to  6.56)
10.56 ( 9.48 to 11.63)
18.31 (15.51 to 21.10)
28.53 (17.84 to 39.23)
HAZARD RATIO
Reference
1.31 (0.93 to  1.85)
1.87 (1.60 to  2.19)
2.39 (2.10 to  2.73)
3.31 (2.96 to  3.69)
5.19 (4.43 to  6.10)
7.33 (5.08 to 10.57)
1 2 3 4 5 6 7 8
Hazard ratio
Figure 1. Adjusted hazard ratios for all outcomes according to number of risk factors among patients with type 
1 diabetes mellitus (T1DM) vs matched controls.  
A, The incidence rate and excess risk (hazard ratio) for all-cause mortality according to number of risk factors at target in 
individuals with T1DM compared with control subjects. B, Incidence rates and hazard ratios for acute myocardial (Continued )
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risk factor and outcome data; clearly, we provide evi-
dence that multiple risk factor control is of paramount 
importance in T1DM.
T1DM was associated with an incremental risk of all-
cause mortality for each risk factor not at target. How-
ever, patients with all risk factors at target demonstrated 
a nonsignificant excess risk of death compared with 
matched controls. Lack of statistical significance does 
not equate to absence of excess risk because the point 
estimate (hazard ratio) was 1.31, which is well above 
1.0. Lack of statistical significance could be due to lack 
of power (which is determined by the number of events). 
Thus, we fail to reject the null hypothesis, but we are 
obliged to redo this analysis in the future when more 
events are at hand.
Even with all 5 risk factors at target, patients with 
T1DM were at excess risk of acute myocardial infarc-
tion and heart failure. The explanations for this remain 
elusive, but there are some plausible explanations. The 
markedly elevated risk of coronary heart disease and 
acute myocardial infarction in T1DM has been known for 
decades; indeed, among all cardiovascular outcomes 
usually assessed, the excess risk appears to be highest 
for coronary heart disease and acute myocardial infarc-
tion. Hyperglycemia seems to accelerate the athero-
sclerotic process.1,7,9,17 Note that individuals with T1DM 
included in our study have had hyperglycemia (even if 
they were below target level at inclusion) for 17 years 
on average. This long duration of hyperglycemia, even if 
well controlled, appears to be driving the excess risk of 
coronary artery disease, and it may not be fully compen-
sated for by optimal risk factor control later in life.18 Per-
haps the same explanation is applicable to heart failure, 
given that recent data show that hyperglycemia may be 
a causal risk factor for the development of heart failure. 
Moreover, it is very likely that many patients in the group 
with all risk factors at target were actually treated (eg, 
with antihypertensives) to target. However, being normo-
tensive on antihypertensive medications may not elimi-
nate the whole risk associated with hypertension (eg, 
some of it will be attributable to systemic inflammation, 
which antihypertensives do not alleviate). The same may 
be applicable to dyslipidemia. Last, if we had required 
the use of cardioprotective mediations and perhaps an 
insulin pump, we would have encircled an even healthier 
group of patients with T1DM, but we decided to not do 
that because we wanted to study a realistic group and 
because we would have lost statistical power.
It may be reasonable to treat some patients even 
more aggressively to further mitigate the excess risks 
associated with T1DM. For example, complications of 
coronary artery disease predominate outcomes in pa-
tients with T1DM,1,7,17 and high-dose statin treatment 
is both safe and effective in reducing the risk of coro-
nary artery disease. Moreover, use of an insulin pump 
is a proven means to improve glycemic control and may 
reduce the risk of cardiovascular outcomes (including 
heart failure), which is why it should be considered early 
in the management of T1DM.19
Our work therefore further underlines the importance 
of other cardiovascular risk factors, besides glycohe-
moglobin, in reducing the risk of all-cause mortality in 
individuals with T1DM.
Our observational study has several strengths but 
also some limitations. Virtually every adult patient with 
T1DM in Sweden was included, with information on co-
existing conditions and other risk factors for all. Fur-
thermore, matched controls were available for compari-
son. There are several limitations. We did not consider 
changes in risk factors during follow-up; we assessed 
only the baseline values to resemble an intention-to-treat 
analysis. Assessing risk factor status during follow-up 
would have resembled a per-protocol analysis, which we 
considered would bring about a high risk of complicated 
reverse causation. In addition, we did not distinguish pa-
tients with optimal risk factors levels de novo from pa-
tients medically treated to attain the optimal risk factor 
targets. We recognize that patients with all risk factors 
at target were better educated and had lower body mass 
index, lower blood pressure, and shorter diabetes dura-
tion than those with several risk factors not at target, 
and although we adjusted for several related factors, we 
acknowledge that residual confounding is impossible to 
fully overcome. The number of stroke events was lim-
ited, providing suboptimal precision of the estimates. It 
is also noteworthy that all point estimates (hazard ratios) 
were above 1.0, and inferences concerning excess risk 
should take into account that few events were noted 
among patients with all risk factors at target.
CONCLUSIONS
Our novel findings from a national cohort suggest that the 
excess mortality in T1DM may be substantially reduced 
with stringent risk factor control. However, the excess risk 
of myocardial infarction and heart failure was still striking 
even with all risk factors at optimal levels. Our data dem-
onstrate incremental cardiovascular risk associated with 
each additional classic cardiovascular risk factor not at op-
timal level, providing strong support for the hypothesis that 
aggressive multifactorial risk factor control for patients 
with T1DM will incrementally improve such outcomes.
Figure 1 Continued. infarction. C and D, Incidence rates and hazard ratios for heart failure and stroke, respectively. Crude 
event rates were calculated as events per 1000 patient-years. Exact Poisson 95% confidence intervals were used. Hazard ratios 
and incidence rates are pooled from all 5 data sets. Number of events and person-years represent the mean in the 5 data sets.
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Figure 2. Adjusted hazard ratios for all-cause mortality according to number of risk factors among male and 
female patients with type 1 diabetes mellitus (T1DM) vs matched controls.  
The figure displays the incidence rate and excess risk (hazard ratio) for all-cause mortality according to number of risk factors at 
target among male and female patients with T1DM compared with control subjects. Crude event rates were calculated as events 
per 1000 patient-years. Exact Poisson 95% confidence intervals were used. Hazard ratios and incidence rates are pooled from 
all 5 data sets. Number of events and person-years represent the mean in the 5 data sets.
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Table 2. Baseline Characteristics of Patients With Type 1 Diabetes Mellitus, Matched Controls, and the 
Imputed Data Sets*
Matched 
Controls
Individuals With Diabetes Mellitus With Complete Data on All 5 Risk Factors
Overall
No. of Risk Factors Beyond Therapeutic Targets
0 1 2 3 4 5
Participants, n
  Complete case data 
set
47 302 9465 958 3399 3237 1474 353 44
  Imputed data set 1 166 529 33 333 2950 10 627 11 120 6433 1963 240
  Imputed data set 2 166 529 33 333 2884 10 664 11 273 6291 1968 253
  Imputed data set 3 166 529 33 333 2917 10 521 11 353 6320 1949 273
  Imputed data set 4 166 529 33 333 2892 10 709 11 219 6322 1937 254
  Imputed data set 5 166 529 33 333 2884 10 666 11 196 6356 1970 261
Women, n (%) 21 714 (45.9) 4345 (45.9) 435 (45.4) 1648 (48.5) 1469 (45.4) 633 (42.9) 145 (41.1) 15 (34.1)
Age, mean (SD), y 32.3 (13.7) 32.3 (13.7) 27.1 (9.7) 28.4 (11.8) 33.7 (14.4) 39.0 (14.3) 40.7 (12.8) 42.2 (9.9)
Marital status, n (%)
  Divorced 2839 (6.0) 575 (6.1) 20 (2.1) 125 (3.7) 223 (6.9) 145 (10.0) 53 (15.1) 9 (20.5)
  Married 11 895 (25.3) 2204 (23.5) 153 (16.0) 627 (18.5) 848 (26.4) 463 (31.9) 100 (28.5) 13 (29.5)
  Single 32 201 (68.6) 6618 (70.4) 782 (81.9) 2635 (77.8) 2138 (66.6) 843 (58.1) 198 (56.4) 22 (50.0)
Education, n (%)
  ≤9 y 9103 (19.7) 1799 (19.3) 118 (12.4) 556 (16.6) 677 (21.2) 350 (24.0) 84 (24.3) 14 (31.8)
  10–12 y 24 416 (52.8) 5133 (55.0) 482 (50.7) 1852 (55.3) 1746 (54.7) 818 (56.1) 208 (60.1) 27 (61.4)
  College/university 12 764 (27.6) 2404 (25.7) 351 (36.9) 939 (28.1) 768 (24.1) 289 (19.8) 54 (15.6) 3 (6.8)
Income quintile, n (%)
  1 (Lowest) 8938 (18.9) 1666 (17.6) 189 (19.7) 689 (20.3) 570 (17.6) 175 (11.9) 40 (11.3) 3 (6.8)
  2 8954 (18.9) 1897 (20.0) 204 (21.3) 735 (21.6) 606 (18.7) 286 (19.4) 58 (16.4) 8 (18.2)
  3 9138 (19.3) 2139 (22.6) 211 (22.0) 749 (22.0) 728 (22.5) 348 (23.6) 93 (26.3) 10 (22.7)
  4 9752 (20.6) 1966 (20.8) 183 (19.1) 639 (18.8) 694 (21.4) 351 (23.8) 80 (22.7) 19 (43.2)
  5 (Highest) 10 507 (22.2) 1797 (19.0) 171 (17.8) 587 (17.3) 639 (19.7) 314 (21.3) 82 (23.2) 4 (9.1)
Immigrants, n (%) 6698 (14.2) 754 (8.0) 80 (8.4) 239 (7.0) 246 (7.6) 143 (9.7) 42 (11.9) 4 (9.1)
Coexisting conditions, n (%)
  Atrial fibrillation 127 (0.3) 23 (0.2) 1 (0.1) 4 (0.1) 7 (0.2) 10 (0.7) 1 (0.3) 0 (0.0)
  Coronary heart 
disease
112 (0.2) 150 (1.6) 2 (0.2) 31 (0.9) 61 (1.9) 48 (3.3) 7 (2.0) 1 (2.3)
  Heart failure 42 (0.1) 40 (0.4) 2 (0.2) 6 (0.2) 19 (0.6) 8 (0.5) 4 (1.1) 1 (2.3)
Information in the National Diabetes Register
  Duration of diabetes 
mellitus, mean (SD), y
 17.3 (13.8) 9.5 (11.4) 13.9 (11.8) 19.0 (13.9) 23.8 (14.3) 25.9 (13.1) 27.1 (11.5)
  Age at onset of 
diabetes mellitus, 
mean (SD), y
 15.0 (7.7) 17.7 (7.3) 14.5 (7.6) 14.7 (7.7) 15.2 (7.8) 14.8 (8.1) 15.1 (9.0)
  HbA1c, mean (SD), 
mmol/mol
 64.8 (15.8) 45.2 (5.6) 62.9 (14.5) 68.1 (14.5) 71.6 (15.0) 74.4 (14.8) 77.6 (15.4)
  LDL cholesterol, mean 
(SD), mg/dL
 2.6 (0.8) 2.3 (0.5) 2.4 (0.6) 2.6 (0.8) 3.1 (0.9) 3.6 (1.0) 4.4 (0.7)
(Continued )
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  Total cholesterol, 
mean (SD), mg/dL
 4.7 (0.9) 4.2 (0.7) 4.4 (0.7) 4.7 (0.9) 5.2 (1.0) 5.8 (1.1) 6.7 (1.0)
  Smoker, n (%)  1256 (13.3) 0 (0.0) 77 (2.3) 440 (13.6) 481 (32.6) 214 (60.6) 44 (100.0)
  Body mass index, 
mean (SD), kg/m2
 25.2 (4.2) 23.9 (3.4) 24.5 (3.7) 25.6 (4.4) 26.5 (4.7) 26.5 (4.6) 26.4 (5.1)
  Systolic blood pressure, 
mean (SD), mm Hg
 124.0 (15.4) 114.2 (8.2) 117.4 (11.2) 127.2 (14.6) 134.1 (16.3) 139.8 (18.5) 143.2 (18.9)
  Diastolic blood pressure, 
mean (SD), mm Hg
 72.7 (9.1) 67.1 (6.3) 69.2 (7.5) 74.7 (8.9) 78.0 (8.4) 80.2 (8.9) 81.7 (14.2)
  No albuminuria, n (%)  8127 (85.9) 958 (100.0) 3345 (98.4) 2899 (89.6) 840 (57.0) 85 (24.1) 0 (0.0)
  Microalbuminuria, 
n (%)
 926 (9.8) 0 (0.0) 49 (1.4) 261 (8.1) 426 (28.9) 163 (46.2) 27 (61.4)
  Macroalbuminuria, 
n (%)
 412 (4.4) 0 (0.0) 5 (0.1) 77 (2.4) 208 (14.1) 105 (29.7) 17 (38.6)
  eGFR, mean (SD), 
mL·min−1·/1.73 m−2
 97.7 (25.2) 100.3 (20.5) 101.7 (22.8) 97.8 (25.2) 90.1 (28.8) 84.6 (29.0) 83.6 (32.9)
Treatment, n (%)
  Statin  1288 (14.0) 37 (3.8) 239 (7.0) 479 (14.7) 388 (26.3) 123 (34.8) 22 (50.0)
  Antihypertensive  1754 (18.5) 36 (3.7) 228 (6.7) 668 (20.6) 594 (40.2) 199 (56.3) 29 (65.9)
eGFR indicates estimated glomerular filtration rate; HbA
1c
, glycohemoglobin; and LDL-C, low-density lipoprotein cholesterol. Survival analyses were 
performed on imputed data sets containing 33 333 persons with type 1 diabetes mellitus. 
Concentrations for HbA
1c
 level are based on values from the International Federation of Clinical Chemistry.
*Baseline data for patients with diabetes mellitus (along with their matched controls) who had complete data for all 5 risk factors assessed (Table 1).
Table 2. Continued
Matched 
Controls
Individuals With Diabetes Mellitus With Complete Data on All 5 Risk Factors
Overall
No. of Risk Factors Beyond Therapeutic Targets
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1 
 
 
 
RANGE OF RISK FACTOR LEVELS/CONTROL, 
MORTALITTY AND CARDIOVASCULAR OUTCOMES IN 
TYPE 1 DIABETES 
 
SUPPLEMENTAL MATERIAL 
 
2 
 
 
Supplementary Table 1. Variables Used in the Imputation Algorithm. 
Age, sex, year of visit, duration of diabetes, age at onset of diabetes, smoking status, use of 
antihypertensive medication, use of lipid lowering medications, albuminuria, LDL cholesterol, 
total cholesterol, body mass index, glycated hemoglobin, systolic blood pressure, diastolic blood 
pressure, marital status, immigrant status, income, education, physical activity, eGFR, county, 
history of coronary heart disease, history of heart failure, history of atrial fibrillation, survival time 
for fatal/nonfatal acute myocardial infarction, outcome for fatal/nonfatal acute myocardial 
infarction, survival time for fatal/nonfatal stroke, outcome for fatal/nonfatal stroke, survival time 
for total mortality, outcome for total mortality. 
 
  
3 
 
 
Supplementary Table 2. Baseline Characteristics of Patients with Type 1 
Diabetes With Missing Data. 
 
Persons with diabetes with 
atleast one missing risk factor  
Persons with diabetes with no 
missing data 
 
  
n 23868 9465 
Females – no. (%)  10942 (45.8)  4345 (45.9) 
Age (years) – mean (SD)  34.0 (13.1) 32.3 (13.7) 
Marital status – no. (%)   
 
   Divorced   1708 (7.2)  575 (6.1) 
   Married   7009 (29.6)  2204 (23.5) 
   Single  14946 (63.2)  6618 (70.4) 
Education – no. (%)   
 
   9 years or less   5184 (22.0)  1799 (19.3) 
   10 to 12 years  12756 (54.2)  5133 (55.0) 
   College/university   5614 (23.8)  2404 (25.7) 
Income  quintile – no. (%)   
 
   Income quintile 1 (lowest)   4868 (20.4)  1666 (17.6) 
   Income quintile 2   5491 (23.0)  1897 (20.0) 
   Income quintile 3   5350 (22.4)  2139 (22.6) 
   Income quintile 4   4562 (19.1)  1966 (20.8) 
   Income quintile 5   3596 (15.1)  1797 (19.0) 
Immigrants – no. (%)   1578 (6.6)  754 (8.0) 
Coexisting conditions – no. (%)   
   Atrial fibrillation     72 (0.3)  23 (0.2) 
   Coronary heart disease    415 (1.7)  150 (1.6) 
   Heart failure    126 (0.5)  40 (0.4) 
Information in the National Diabetes 
Register 
 
 
Duration of diabetes – mean (SD)  18.7 (13.4) 17.3 (13.8) 
Age at onset of diabetes – mean (SD)  15.3 (7. 7) 15.0 (7.7) 
Glycated haemoglobin – mean (SD)  66.3 (15.9) 64.8 (15.8) 
LDL cholesterol – mean (SD)   2.7 (0.8) 2.6 (0.8) 
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Total cholesterol – mean (SD)   4.8 (1.1) 4.7 (0.9) 
Smoker – no. (%)   2968 (14.0)  1256 (13.3) 
Body Mass Index  – mean (SD)  25.1 (3.9) 25.2 (4.2) 
Systolic blood pressure – mean (SD) 126.3 (16.4) 124.0 (15.4) 
Diastolic blood pressure – mean (SD)  73.7 (9.05) 72.7 (9.1) 
Albuminuria – n (%)    
   No albuminuria  14336 (84.3)  8127 (85.9) 
   Microalbuminuria   1440 (8.5)  926 (9.8) 
   Macroalbuminuria   1225 (7.2)  412 (4.4) 
eGFR – mean (SD) 100.7 (26.3) 97.7 (25.2) 
Treatment – no. (%)  
   Statin – no (%)  1288 (14.0) 
  Antihypertensive – no (%)  1754 (18.5) 
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Supplementary Figure 1: Flow chart of study cohort and analyses performed. 
Participants may fulfill more than one exclusion criteria.
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Supplementary Figure 2. Distribution of variables used as pr edictors in the multiple imputation.  Variables that were included in 
the MICE algorithm to impute missing data for patients with T1DM. Five complete data sets were imputed. Supplemental Figure 2 
shows, along with the frequency of missing data elements, the distribution of each parameter before imputation.
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Supplementary Figure 5. Number Of Risk Factors Among Patients With T1DM According To Year.  
The y-axis displays calendar year and the x-axis displays the proportion of patients in each risk factor category. 
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Supplementary Figure 6. Primary Causes of Death in the Cohort. Primary causes of death  
as given in the death certificates cause of death was missing for 2 matched controls. 
